## Alembic Pharmaceuticals Limited (APLLTD) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Alembic Pharmaceuticals Limited (APLLTD) is a pharmaceutical company listed on the Indian stock exchange since September 20, 2011.  The company operates within the Pharmaceuticals & Biotechnology sector, specifically focusing on the manufacturing and distribution of pharmaceutical products.  Further details on its market positioning within the sector require additional research beyond the provided data.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,054.00       |                                                                      |
| Percentage Change (PChange) | 0.59%           | Positive change indicating recent upward price movement.             |
| Pre-Open Activity          | Mixed           | Pre-open orders show some buying interest but also selling pressure. |
| Week High                    | ₹1,303.90       | Significant high indicating recent volatility.                       |
| Week Low                     | ₹746.00         | Significant low indicating recent volatility.                       |
| VWAP                        | ₹1,061.06       | Volume Weighted Average Price slightly higher than closing price.     |
| Sector PE                   | 32.4            |                                                                      |
| Symbol PE                   | 31.9            | Slightly lower than sector PE, suggesting potential undervaluation. |
| Delivery Percentage         | 39.45%          | Relatively low delivery percentage suggests some speculative trading. |
| Market Depth                | Low             | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The provided financial data shows a mixed picture. While revenue and profit after tax have generally increased over the past five quarters, the growth rate has fluctuated.  EPS has also shown some variability.  Key financial ratios (like Debt Service Coverage Ratio and Interest Service Coverage Ratio) are available but require further analysis to determine their significance relative to industry benchmarks.  Detailed analysis requires access to balance sheets and cash flow statements.

| Quarter      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹) |
|--------------|-----------------|-----------------|-----------------------|---------|
| Q2 FY25 (Sep) | 159,640.8       | 140,926         | 16,578.2              | 8.43    |
| Q1 FY25 (Jun) | 147,870.2       | 126,550.2        | 17,619.1              | 8.96    |
| Q4 FY24 (Mar) | 148,177.5       | 126,561.1        | 20,187.1              | 10.27   |
| Q3 FY24 (Dec) | 159,169.4       | 133,499.3        | 23,324.4              | 11.87   |
| Q2 FY24 (Sep) | 148,779.5       | 135,395.4        | 13,384.1              | 6.81    |


**4. Corporate Actions and Announcements:**

APLLTD has a history of paying dividends, with recent payouts ranging from ₹8 to ₹11 per share.  The provided data includes ex-dates and purposes for these dividends.  Recent announcements include press releases and updates, but their specific impact on stock performance requires further investigation.  No upcoming corporate actions are explicitly mentioned.

**5. Shareholding Patterns:**

Promoter and public shareholding have remained relatively stable over the past five quarters.  There are no significant shifts or trends observed in the provided data.

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 69.61                        | 30.39      | 0.00                           | 100.00    |
| 31-Dec-2023  | 69.61                        | 30.39      | 0.00                           | 100.00    |
| 31-Mar-2024  | 69.61                        | 30.39      | 0.00                           | 100.00    |
| 30-Jun-2024  | 69.61                        | 30.39      | 0.00                           | 100.00    |
| 30-Sep-2024  | 69.61                        | 30.39      | 0.00                           | 100.00    |


**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week high and low.  The relatively low market depth further contributes to the risk.  The risk-reward profile needs further assessment considering industry benchmarks and future growth prospects.  The provided CM Annual Volatility (42.8%) is high, indicating substantial price fluctuations.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Relatively stable promoter holding.
* Potential undervaluation based on PE ratio compared to the sector.


**8. Disadvantages and Risks:**

* High volatility and low market depth.
* Fluctuating financial performance.
* Dependence on the pharmaceutical sector's overall performance and regulatory changes.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price increase and mixed pre-open activity suggest caution.  High volatility makes short-term trading risky.

* **Medium-term (3 to 12 months): Hold.**  The company's financial performance needs further evaluation to determine its medium-term growth potential.  Upcoming corporate actions and industry trends will also influence the outlook.

* **Long-term (1 year and beyond): Hold/Consider Buy (with caution).**  The consistent dividend payouts and stable promoter holding suggest long-term stability. However, thorough due diligence is required to assess the company's long-term growth prospects and competitive landscape.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Profitable, but fluctuating performance needs further analysis)
* Market Performance: 6/10 (Positive recent change, but high volatility and low market depth)
* Volatility and Risk: 4/10 (High volatility and low market depth are significant risks)
* Corporate Actions & Governance: 8/10 (Consistent dividend payouts and stable promoter holding)
* Shareholding Patterns: 7/10 (Stable shareholding pattern)

**Analysis Score (out of 10): 8/10**

* Completeness and utilization of data: 9/10 (Most data points were used effectively)
* Accuracy and clarity of analysis: 8/10 (Analysis is clear, but some aspects require further investigation)
* Professional formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data, Alembic Pharmaceuticals Limited (APLLTD) presents a mixed investment opportunity. While the company shows some strengths, such as consistent dividend payments and stable promoter holding, the high volatility and fluctuating financial performance introduce significant risks.  A "Hold" recommendation is given for the short and medium term, with a cautious "Hold/Consider Buy" for the long term, contingent upon further due diligence and a more comprehensive financial analysis.  Investors should carefully consider their risk tolerance before making any investment decisions.  Additional research is crucial to gain a more complete understanding of the company's future prospects.
